Axinat-F (25 mcg+125 mcg)/puff Powder Inhaler

Axinat-F (25 mcg+125 mcg)/puff Powder Inhaler — Clinical Overview

What is Axinat-F 25+125 mcg Powder Inhaler?

Axinat-F (25 mcg+125 mcg) is a fixed-dose combination dry powder inhaler (DPI) manufactured by ACI Limited, Bangladesh. Each actuation delivers salmeterol 25 mcg (a long-acting beta-2 agonist, LABA) and fluticasone propionate 125 mcg (an inhaled corticosteroid, ICS) simultaneously. This ICS/LABA combination addresses both key pathophysiological components of obstructive airway disease: bronchoconstriction and airway inflammation.

Combining an ICS with a LABA in a single inhaler has three practical advantages over separate inhalers: improved adherence, guaranteed ICS co-administration (eliminating LABA monotherapy risk in asthma), and convenience. The 25+125 mcg strength is suitable for moderate asthma and COPD patients who need medium-intensity ICS coverage.

Mechanism of Action

The two components act synergistically on different but complementary pathways:

• Salmeterol (LABA): Binds to beta-2 adrenergic receptors on bronchial smooth muscle, causing relaxation and bronchodilation lasting up to 12 hours. Also stabilises mast cells and reduces mediator release. Does NOT treat underlying airway inflammation.
• Fluticasone propionate (ICS): Binds to glucocorticoid receptors in airway epithelial and inflammatory cells, suppressing the production of pro-inflammatory cytokines (IL-4, IL-5, IL-13), reducing eosinophilic inflammation, decreasing airway hyper-responsiveness, and preventing remodelling. Fluticasone has very high local potency but low systemic bioavailability (~1% from inhaled dose) when used correctly with a DPI.
• Synergy: ICS upregulates beta-2 receptors (maintaining LABA responsiveness); LABA increases glucocorticoid receptor nuclear translocation (enhancing ICS anti-inflammatory effect). Together they achieve greater benefit than either drug alone.

Indications

• Asthma (Step 3–4): Patients ≥12 years whose asthma is not adequately controlled on ICS alone. Also appropriate as initial maintenance therapy in patients with moderate-to-severe asthma
• COPD (moderate to very severe): Patients with FEV1 <60% predicted with a history of ≥1 exacerbation per year despite regular bronchodilator therapy

Dosage and Administration

• Asthma (adults/adolescents ≥12 years): 1 puff (25+125 mcg) twice daily — morning and evening
• COPD: 1 puff (25+125 mcg) twice daily

DPI technique: Open the device, load the dose as per device instructions. Exhale fully away from the device, place mouthpiece between lips, inhale quickly and deeply, hold breath for 10 seconds, exhale slowly. Rinse mouth with water and spit after each use — this is critical to prevent oral candidiasis from fluticasone deposition in the mouth.

Choosing Between Axinat-F 25+125 and Axinat-F 25+250

Diabetes and ICS/LABA — Special Considerations

Axinat-F is commonly used by diabetic patients with co-existing respiratory disease. Several diabetes-specific considerations apply:

• Fluticasone and blood glucose: Inhaled fluticasone at 125 mcg/puff has very low systemic bioavailability from a DPI (predominantly lung delivery). Clinically significant steroid-induced hyperglycaemia is uncommon at this dose but may occur in susceptible individuals — particularly those with borderline glycaemia or on high total daily inhaled steroid doses. Monitor blood glucose when starting or stepping up therapy.
• COPD exacerbations and systemic steroids: When COPD exacerbations are prevented by effective ICS/LABA, the patient avoids systemic corticosteroid courses — which routinely cause significant hyperglycaemia in diabetics. Axinat-F's preventive benefit in this context is significant.
• Salmeterol and glucose: Beta-2 agonists stimulate glycogenolysis. At standard inhaled doses, this effect is minor — but patients with already elevated glucose levels may notice small increases. Monitor at initiation.
• No pharmacokinetic drug interactions: Salmeterol and fluticasone do not interact pharmacokinetically with metformin, insulin, DPP-4 inhibitors, or SGLT-2 inhibitors. CYP3A4 inhibitors (e.g., itraconazole, ritonavir) can increase fluticasone plasma levels — consult your pharmacist if taking antifungals or antiretrovirals.
• Inhaler technique in neuropathy: Diabetic patients with peripheral neuropathy and reduced hand dexterity may struggle with DPI devices — assess technique at each visit.

Side Effects

• Common: Oral candidiasis (thrush), hoarseness/dysphonia — rinse mouth after every use
• Common (salmeterol): Tremor, palpitations, headache
• Uncommon: Paradoxical bronchospasm, minor blood glucose elevation, hypokalaemia
• Rare: Adrenal suppression (with high doses or prolonged use), cataracts, glaucoma, decreased bone density (all much less common than with systemic steroids at these inhaled doses)

Contraindications

• Not for acute bronchospasm or status asthmaticus (use SABA for rescue)
• Known hypersensitivity to salmeterol, fluticasone propionate, or any excipient

Frequently Asked Questions (FAQ)